Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC102 versus oral prednisolone for idiopathic sudden sensorineural hearing loss
NL-OMON60847Phase 2Completed
- Sponsor
- AudioCure Pharma GmbH
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in idiopathic sudden sensorineural hearing loss (ISSNHL) comparing AC102 intratympanic injection with Oral prednisolone (2 arms). Primary endpoint: Mean change in hearing threshold to Day 28. Started Mar 2023; status: completed.
02
Drugs
AC102prednisolone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NL-OMON60847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60847.